Epialfa 50mg Injection
Marketer
Metta Life Sciences Private Limited
Salt Composition
Epirubicin (50mg)
Overview Epialfa 50mg Injection
Epialfa 50mg Injection treats various hematologic malignancies and cancers affecting the breast, stomach, lungs, ovaries, and soft tissues. It also aids in preventing bladder cancer recurrence post-surgery. Administered intravenously by a healthcare professional, this medication may be used alone or in combination with other drugs as part of a chemotherapy regimen. Dosage and frequency are determined by your physician based on your specific condition and may vary. Strict adherence to the prescribed regimen is crucial; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic benefits may not be immediately apparent, requiring several weeks or months; discontinue only upon your doctor's instruction. Note that Epialfa reduces contraceptive efficacy; reliable birth control is advised for both partners during treatment. Common side effects encompass nausea, thrombocytopenia, alopecia, amenorrhea, pyrexia, and skin rashes. The drug's effect on blood cell counts increases infection risk, potentially life-threatening. Regular blood tests to monitor blood cell levels, renal, hepatic, and cardiac function are essential. Prior to treatment, disclose any existing liver or heart conditions, and provide a complete list of all medications being taken, as interactions may compromise efficacy or alter the drug's action. Inform your doctor of pregnancy or breastfeeding.
Uses of Epialfa 50mg Injection
Malignancy
Major Benefits of Epialfa 50mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Epialfa 50mg Injection:
- Low blood platelets
- Nausea
- Hair loss
- Absence of menstrual periods
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Weight loss
- Decreased white blood cell count (neutrophils)
- Hot flashes
- Gastrointestinal inflammation
- Rash
- Low energy
- Eye disorder
How to use Epialfa 50mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Epialfa 50mg Injection works:
Epialfa 50mg Injection is a cancer therapeutic agent targeting breast cancer. Its mechanism involves inhibiting topoisomerase II, a crucial enzyme in breast cancer cell DNA replication. This inhibition, coupled with the generation of cytotoxic free radicals, leads to DNA damage, ultimately arresting and eliminating malignant breast cells.
SAFETY ADVICE
AlcoholUNSAFE
Alcohol consumption alongside Epialfa 50mg Injection is contraindicated.
PregnancyCONSULT YOUR DOCTOR
Administering Epialfa 50mg Injection during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential advantages outweigh the known hazards. Physician consultation is mandatory.
Breast feedingUNSAFE
Administering Epialfa 50mg Injection while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Epialfa 50mg Injection can produce adverse reactions that might impact driving capabilities. Nausea and vomiting, potential side effects of Epialfa 50mg Injection, may temporarily hinder safe driving.
KidneySAFE IF PRESCRIBED
Epialfa 50mg Injection appears to pose minimal risk for individuals with kidney impairment. Preliminary findings indicate dose modification for Epialfa 50mg Injection might be unnecessary in such cases. However, physician consultation is advised. Reduced dosages should be evaluated for patients exhibiting serum creatinine exceeding 5 mg/dL.
LiverCAUTION
Epialfa 50mg Injection requires careful administration to individuals with hepatic impairment. Dosage modification may be necessary. Physician consultation is advised. The injection is contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Epialfa 50mg Injection :
NA
Facts to Know About Epialfa 50mg Injection
| Label | Value |
|---|---|
| Chemical Category | Anthracycline-based drug |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavioral Class | Cytotoxic alkaloids |
3,018 People bought this recently